Actos Bladder Cancer Lawsuit
Actos recall not recommended by European health regulators

Actos® was first introduced in July of 1999. Prescribed to treat type II diabetes, the drug became popular for its ability to effectively regulate insulin. In September of 2010, Actos became so successful that it brought in revenues for Takeda Pharmaceuticals of $4.3 billion. Although millions of patients have taken Actos, many of them have filed complaints against Takeda Pharmaceuticals claiming that Actos effects include bladder cancer. Takeda Pharmaceuticals has also been accused of not appropriately researching the product and failed to issue proper warnings. After performing a thorough review of the product, the Food and Drug Administration (FDA) issued new warning labels in August 2011. While Actos has been linked to an increased risk in bladder cancer, European drug regulators do not recommend an Actos recall just yet. Rather, doctors suggest that Actos be prescribed only as a second or third choice medication for patients diagnosed with type II diabetes. A clarification statement regarding these safety concerns was released by the European Medicines Agency (EMA) on October 21, 2011. The EMA argues that Actos is still a valid diabetes treatment and recommend that it should be prescribed only if other medications fail. In July 2011, the EMA’s Committee for Medicinal Products for Human Use (CHMP) determined that some diabetes patients still require use of Actos because other medications have failed to effectively treat diabetes. Anyone that is prescribed Actos is recommended to have a careful pre-screening performed by a healthcare professional along with close monitoring to check for possible bladder cancer in the future. A decision has not yet been reached regarding whether the drug will be banned or not. The U.S. Judicial Panel on Multidistrict Litigation met on December 1, 2011 in an oral hearing regarding consolidation for Actos bladder cancer lawsuits. Currently no reports have been released regarding final decisions.     


About the Contributor

Related Posts